Skip to main content
Evidence Snapshot

Estrogen receptor

CHEMBL206 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T17:32:34Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL206
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Estrogen receptor as ChEMBL target CHEMBL206, mapped to UniProt P03372. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Estrogen receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL206
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P03372
Estrogen receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Estrogen receptor matters

As of 2026-09-13

Estrogen receptor is reviewed as Estrogen receptor (UniProt P03372); Estrogen receptor shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.; 11 linked drugs keep this evidence frame grounded.; the current evidence base includes 52 approved drugs, 9920 compounds, and 1783 assays, with lead potency reaching pChEMBL 11.0.

Disease context
breast cancer

Estrogen receptor shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AMCENESTRANT, BRILANESTRANT, CAMIZESTRANT.

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include AMCENESTRANT, BRILANESTRANT, CAMIZESTRANT, ELACESTRANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 11 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 52 approved drugs, 9920 compounds, and 1783 assays for this target. The dominant activity type is IC50. CHEMBL135 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL135 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
52 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Estrogen receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P03372, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why breast cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

9920
Total Compounds
1783
Total Assays
52
Approved Drugs
IC50: 7551.0, KI: 1697.0, EC50: 1485.0, KD: 56.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL135
 11.0 EC50 Approved
No preferred name
CHEMBL4591338
 11.0 IC50 —
No preferred name
CHEMBL5177342
 10.8 EC50 —
No preferred name
CHEMBL149791
 10.8 EC50 —
No preferred name
CHEMBL4439408
 10.7 IC50 —

Approved Drugs

Structure Compound First Approval
ELACESTRANT
CHEMBL4297509
 2023
ESTETROL ANHYDROUS
CHEMBL1230314
 2021
BAZEDOXIFENE
CHEMBL46740
 2009
LASOFOXIFENE
CHEMBL328190
 2009
FULVESTRANT
CHEMBL1358
 2002
ESTRIOL
CHEMBL193482
 2000
RALOXIFENE HYDROCHLORIDE
CHEMBL1116
 1997
RALOXIFENE
CHEMBL81
 1997
ETHINYL ESTRADIOL
CHEMBL691
 1982
ESTRONE
CHEMBL1405
 1979
TAMOXIFEN
CHEMBL83
 1977
ESTRADIOL
CHEMBL135
 1975
DIETHYLSTILBESTROL
CHEMBL411
 1973
ETHYLESTRENOL
CHEMBL1200623
 1964
STANOZOLOL
CHEMBL2079587
 1962
NORETHINDRONE
CHEMBL1162
 1962
MESTRANOL
CHEMBL1201151
 1961
CYCLOFENIL
CHEMBL141305
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T17:32:34Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL206